ATE485399T1 - Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon - Google Patents
Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davonInfo
- Publication number
- ATE485399T1 ATE485399T1 AT07734854T AT07734854T ATE485399T1 AT E485399 T1 ATE485399 T1 AT E485399T1 AT 07734854 T AT07734854 T AT 07734854T AT 07734854 T AT07734854 T AT 07734854T AT E485399 T1 ATE485399 T1 AT E485399T1
- Authority
- AT
- Austria
- Prior art keywords
- diabetes
- arntl2 gene
- insulin
- type
- present
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000008867 ARNTL Transcription Factors Human genes 0.000 title 1
- 108010088547 ARNTL Transcription Factors Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77666206P | 2006-02-27 | 2006-02-27 | |
| PCT/IB2007/001649 WO2007099461A2 (en) | 2006-02-27 | 2007-02-27 | Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485399T1 true ATE485399T1 (de) | 2010-11-15 |
Family
ID=38442622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07734854T ATE485399T1 (de) | 2006-02-27 | 2007-02-27 | Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20090181915A1 (enExample) |
| EP (1) | EP1994174B1 (enExample) |
| JP (1) | JP2009528030A (enExample) |
| AT (1) | ATE485399T1 (enExample) |
| CA (1) | CA2638825A1 (enExample) |
| DE (1) | DE602007009944D1 (enExample) |
| WO (1) | WO2007099461A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090181915A1 (en) | 2006-02-27 | 2009-07-16 | Institut Pasteur | Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes |
| CN109295210A (zh) * | 2018-10-30 | 2019-02-01 | 深圳市万众基因转化医学研究院 | 一种人类2型糖尿病相关基因突变筛查的组合引物及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3769465B2 (ja) * | 2001-02-13 | 2006-04-26 | 独立行政法人科学技術振興機構 | 新規時計遺伝子Ｂｍａｌ２ |
| WO2006019824A2 (en) * | 2004-07-15 | 2006-02-23 | Joslin Diabetes Center, Inc. | Methods of treating diabetes |
| US20090181915A1 (en) | 2006-02-27 | 2009-07-16 | Institut Pasteur | Transcription factor arntl2 gene and expression products thereof used in the diagnosis, prevention, and treatment of type 1 diabetes |
-
2007
- 2007-02-27 US US12/280,822 patent/US20090181915A1/en not_active Abandoned
- 2007-02-27 US US11/679,492 patent/US7960107B2/en not_active Expired - Fee Related
- 2007-02-27 WO PCT/IB2007/001649 patent/WO2007099461A2/en not_active Ceased
- 2007-02-27 DE DE602007009944T patent/DE602007009944D1/de active Active
- 2007-02-27 AT AT07734854T patent/ATE485399T1/de not_active IP Right Cessation
- 2007-02-27 EP EP07734854A patent/EP1994174B1/en not_active Not-in-force
- 2007-02-27 JP JP2008555900A patent/JP2009528030A/ja not_active Withdrawn
- 2007-02-27 CA CA002638825A patent/CA2638825A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007099461A3 (en) | 2007-12-27 |
| US20070214510A1 (en) | 2007-09-13 |
| EP1994174B1 (en) | 2010-10-20 |
| CA2638825A1 (en) | 2007-09-07 |
| DE602007009944D1 (de) | 2010-12-02 |
| HK1126251A1 (en) | 2009-08-28 |
| US20090181915A1 (en) | 2009-07-16 |
| JP2009528030A (ja) | 2009-08-06 |
| EP1994174A2 (en) | 2008-11-26 |
| US7960107B2 (en) | 2011-06-14 |
| WO2007099461A2 (en) | 2007-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| WO2009038689A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| DE602004007808D1 (de) | Neue gamma secretase inhibitoren | |
| EA201201650A1 (ru) | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения | |
| BR0304653A (pt) | Método para estimativa de maturidade de segurança | |
| DK1143955T3 (da) | En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes | |
| NO20082790L (no) | Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion | |
| AR057631A1 (es) | Composiciones y metodos para incrementar la sensibilidad a insulina | |
| DE602004021847D1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| ATE383870T1 (de) | Behandlung von neurodegenerative krankheiten mit gpr49 | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| ATE485399T1 (de) | Gen des transkriptionsfaktors arntl2 sowie bei der diagnose, vorbeugung und behandlung von typ-1-diabetes verwendete expressionsprodukte davon | |
| DE602007010459D1 (de) | Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie | |
| ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| ATE546547T1 (de) | Diagnose der chronischen abstossung | |
| MX2009004792A (es) | Moduladores de la union de pai-1 para el tratamiento de trastornos oculares. | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| ATE486612T1 (de) | Verfahren zur behandlung von diabetes typ 2 | |
| WO2004109290A3 (en) | Methods for identifying modulators of kinesin activity | |
| ATE455577T1 (de) | Behandlung von neurodegenerativen erkrankungen durch verwendung von laptm4b | |
| WO2010079340A3 (en) | Methods for identifying compounds modulating type-i transmebrane matrix metalloproteinase (mmp) | |
| ATE549352T1 (de) | Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms | |
| DE602004013283D1 (de) | Diagnostisches verfahren der mastozytose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |